Powered by 
Technavio
VBI Vaccines Inc. | Data-Driven Analysis and Industry Review
Published: August 21, 2024VBI Vaccines Inc. is a biotechnology company focused on developing enveloped virus platform technology for the prevention and treatment of diseases. The company's proprietary technology involves using enveloped viruses as vectors to elicit a robust immune response against specific antigens. VBI's pipeline includes vaccines for hepatitis B, influenza, and cytomegalovirus (CMV), among others. The company's lead product, Sci-B-Vac, is a hepatitis B vaccine that uses its enveloped virus platform technology. VBI is headquartered in Cambridge, Massachusetts, and has research and development facilities in Rehovot, Israel. The company's mission is to address unmet medical needs by developing and commercializing innovative, effective, and safe preventive and therapeutic interventions for a range of diseases.'
1. Focus on developing enveloped virus platform technology for infectious diseases: VBI Vaccines specializes in creating preventive vaccines using its enveloped virus like particle (eVLP) technology, which mimics the protective shell of the virus without the infectious genetic material.
2. Collaborative partnerships and strategic alliances: The company has formed several collaborations with academic institutions, government agencies, and industry partners to advance its pipeline of vaccines, including partnerships with the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA).
3. Clinical-stage pipeline: VBI Vaccines has a diverse pipeline of vaccine candidates, with several in clinical development for infectious diseases such as hepatitis B, cytomegalovirus (CMV), and COVID-19.
4. Strong intellectual property position: The company holds a broad intellectual property portfolio, including over 300 issued and pending patents, which protects its eVLP technology and vaccine candidates.
5. Experienced management team: VBI Vaccines' management team has extensive experience in the biotech industry, with a track record of successfully developing and commercializing vaccines. This expertise is essential in navigating the complex regulatory landscape and bringing vaccines to market.
1. VBI Vaccines is a biotech company specializing in the development of enveloped virus-like particle (eVLP) based vaccines, using its proprietary technology platform, Envelope Protein Platform (eVP).
2. The company focuses on addressing unmet medical needs in infectious diseases and immuno-oncology, with a pipeline of preventive and therapeutic vaccines in various stages of development.
3. VBI Vaccines leverages its BI capabilities to analyze clinical, preclinical, and real-world data to inform and optimize vaccine design, development, and clinical trial strategies.
4. The company's Business Intelligence team utilizes advanced analytics tools and techniques, such as machine learning and predictive modeling, to identify trends, patterns, and insights from complex data sets.
5. VBI Vaccines' data-driven approach to vaccine development aims to improve efficacy, reduce development timelines, and enhance the overall value of its pipeline candidates.
Browse Our Research Portfolio In VBI Vaccines Inc. Markets
Health Care
Pharmaceuticals
Pharmaceuticals
About Technavio
With unparalleled market insights, our research is designed to elevate your business to new heights. Technavio stands at the forefront of market research with a global perspective. Our approach is grounded in four key principles: accessible reports, comprehensive industry analysis, a focus on innovative and emerging technologies, and competitive pricing. We are dedicated to empowering companies and executives to make informed, timely, and strategic decisions.
